Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.

Vyfhuis MAL, Bhooshan N, Burrows WM, Turner M, Suntharalingam M, Donahue J, Nichols EM, Feliciano J, Bentzen SM, Badiyan S, Carr SR, Friedberg J, Simone CB, Edelman MJ, Feigenberg SJ, Mohindra P.

Open source

DOI
10.1016/j.adro.2017.07.009
Published
2017-07-31
Container
Adv Radiat Oncol
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.adro.2017.07.009,
  title = {Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.},
  author = {Vyfhuis MAL and  Bhooshan N and  Burrows WM and  Turner M and  Suntharalingam M and  Donahue J and  Nichols EM and  Feliciano J and  Bentzen SM and  Badiyan S and  Carr SR and  Friedberg J and  Simone CB and  Edelman MJ and  Feigenberg SJ and  Mohindra P.},
  year = {2017},
  journal = {Adv Radiat Oncol},
  doi = {10.1016/j.adro.2017.07.009},
  url = {https://doi.org/10.1016/j.adro.2017.07.009}
}

RIS

TY  - JOUR
TI  - Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.
AU  - Vyfhuis MAL
AU  -  Bhooshan N
AU  -  Burrows WM
AU  -  Turner M
AU  -  Suntharalingam M
AU  -  Donahue J
AU  -  Nichols EM
AU  -  Feliciano J
AU  -  Bentzen SM
AU  -  Badiyan S
AU  -  Carr SR
AU  -  Friedberg J
AU  -  Simone CB
AU  -  Edelman MJ
AU  -  Feigenberg SJ
AU  -  Mohindra P.
PY  - 2017
JO  - Adv Radiat Oncol
DO  - 10.1016/j.adro.2017.07.009
UR  - https://doi.org/10.1016/j.adro.2017.07.009
ER  - 

APA

MAL, V., N, B., WM, B., M, T., M, S., J, D., EM, N., J, F., SM, B., S, B., SR, C., J, F., CB, S., MJ, E., SJ, F., & P., M. (2017). Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.. Adv Radiat Oncol. https://doi.org/10.1016/j.adro.2017.07.009

Source records